Hints and tips:
Related Special Reports
...Pfizer products such as Paxlovid, combined Covid and flu test Lucira, and recently approved migraine nasal spray Zavzpret will be available on the site....
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...He said its products complied with the EU’s “extremely strict” production standards and that its factories were comparable “to the Pfizers of the world”....
...Soriot’s new pay deal comes after the company hit a $45bn sales target in 2023 that the chief executive had set in 2014 when the company fended off a takeover bid from US rival Pfizer....
...GSK has sued Pfizer and BioNTech, alleging that their pharmaceutical rivals’ Covid-19 vaccine infringed “revolutionary” mRNA patents the British company filed in 2010....
...This included a Merck agreement with Daiichi Sankyo worth up to $22bn, Pfizer’s $43bn acquisition of lossmaking Seagen and AbbVie’s $10.1bn acquisition of ImmunoGen....
...In February, the UK pharmaceuticals company hit a long-term sales target that once seemed out of reach....
...The announcement comes after the pharmaceutical group requested in March that the European Union marketing authorisation for Vaxzevria be withdrawn, a request that was granted on Tuesday....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...Stocks like Moderna: But also Novavax: Cansino Biologics: Inovio Pharmaceuticals: Arcturus: Vaxart: Ibio: And Dynavax: It’s not just a Covid story....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...The partnership strengthens Sanofi, one of the world’s largest vaccine makers by sales, in the post-pandemic Covid jab market, where pharmaceutical groups are increasingly focused on combined shots against...
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...Vaccine hopes and demand for medical treatments also buoyed pharmaceutical groups such as Moderna and Pfizer in 2020, as well as lesser-known Chinese groups, including WuXi Biologics, Chongqing Zhifei Biological...
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...Pfizer: The pharmaceutical company is expected to report that quarterly revenue declined 23.4 per cent from the same period last year to $14bn, according to LSEG, as the company faces weak demand for its...
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Shares in consumer pharmaceutical group Haleon rose 8 per cent on Thursday after it forecast stronger than anticipated sales for 2024 and announced share buybacks worth £500mn....
...He now hopes to bring a case to trial alleging that the product — sold by GSK, Sanofi, Pfizer and Boehringer Ingelheim over many years, caused his disease....
International Edition